Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%

Stock Information for Akorn

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akorn

Akorn Provides Second Quarter 2020 Results
Akorn Animal Health Announces Launch of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment
Akorn Provides First Quarter 2020 Results
Enphase Energy and Paylocity Set to Join S&P MidCap 400; Core Laboratories and Meredith to Join S&P SmallCap 600
Akorn Provides Update on Sale Process
Akorn Provides Fourth Quarter and Full Year 2019 Results
Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business
Akorn Continues Negotiations with Lenders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.